Advertisement

Topics

Novartis Launches Patient Trial for Compound Against Multidrug-Resistant Malaria

09:47 EDT 22 Aug 2017 | PharmPro

Novartis and Medicines for Malaria Venture launch patient trial in Africa for KAF156, a novel compound against multidrug-resistant malaria. It has the potential to be a game-changer in malaria elimination, rapidly clearing malaria infection.
Contributed Author: 
Novartis Pharmaceuticals Corp.

Original Article: Novartis Launches Patient Trial for Compound Against Multidrug-Resistant Malaria

NEXT ARTICLE

More From BioPortfolio on "Novartis Launches Patient Trial for Compound Against Multidrug-Resistant Malaria"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Malaria
Malaria is a serious tropical disease spread by mosquitoes. If malaria is not diagnosed and treated promptly, it can be fatal. What causes malaria? Malaria is caused by a type of parasite known as Plasmodium. There are many different types of Plasmod...